So far, one B.C. resident who purchased 220 shares at $1.45 per stock is listed as a plaintiff in the lawsuit, which was filed by Vancouver law firmThe notice of claim alleges the plaintiff and other prospective class action members suffered losses and damages as a result of purchasing Adastra shares between the time of the inaccurate statements’ publication and the “corrective disclosure.”
In an emailed statement, Saro Turner, a partner at Slater Vecchio, said their job is to “stand up for” investors and “help them get the compensation they deserve.”The proposed class action suit is on behalf of any investors who purchased common shares in Adastra and held them between Feb. 22 and March 3, and still held those shares as of March 3.
that while Adastra is allowed to produce cocaine under its amended licence, it is only permitted to sell the drug to other controlled substance licence holders, such as pharmacists, practitioners, hospitals, or those with an exemption for research purposes.Article content Adastra Labs is the second B.C. company now licensed to produce, sell and distribute cocaine, as well as opium and ecstasy.